This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
Blood Cancer Journal Open Access 18 August 2023
-
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
Leukemia Open Access 02 December 2022
-
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma
Experimental Hematology & Oncology Open Access 15 October 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shaffer Al 3rd, Young RM, Staudt LM . The biology of human lymphoid malignancies revealed by gene expression profiling. Ann Rev Immunol 2012; 30: 565–610.
Pasqualucci L . The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hemmatol 2013; 20: 336–344.
Ahmad SS, Idris SF, Follows GA, Williams MV . Primary testicular lymphoma. Clin Oncol 2012; 24: 358–365.
Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011; 29: 2766–2772.
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676–1679.
Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717–721.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88–92.
Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115–119.
Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203–5211.
Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M . Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122: 791–792.
Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJM, Oud MECM, Scheepstra C et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immuneprivileged sites. Blood Cancer J 2013; 3: e139.
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012; 367: 826–833.
Pals ST, de Gorter DJ, Spaargaren M . Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007; 110: 3102–3111.
de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590–2594.
Lim KH, Romero DL, Chaudhary D, Robinson SD, Staudt LM . IRAK4 kinase as a novel therapeutic target in the abc subtype of diffuse large B cell lymphoma. ASH Annual Meeting Abstracts 2012; 120: 62.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Kraan, W., van Keimpema, M., Horlings, H. et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 28, 719–720 (2014). https://doi.org/10.1038/leu.2013.348
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.348
This article is cited by
-
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
Leukemia (2023)
-
The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
Blood Cancer Journal (2023)
-
Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities
Virchows Archiv (2023)
-
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma
Experimental Hematology & Oncology (2022)
-
Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas
Virchows Archiv (2022)